Literature DB >> 32112923

Cyclosporine and omalizumab together: A new option for chronic refractory urticaria.

Jorge Sánchez1, Leidy Alvarez2, Ricardo Cardona2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32112923     DOI： 10.1016/j.jaip.2020.02.012

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  3 in total

Review 1.  Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.

Authors:  Liting He; Wanyu Yi; Xin Huang; Hai Long; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-16       Impact factor: 8.667

2.  Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria.

Authors:  Maria Maddalena Sirufo; Enrica Maria Bassino; Francesca De Pietro; Lia Ginaldi; Massimo De Martinis
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

3.  Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Authors:  Emek Kocatürk; Emel Bülbül Başkan; Özlem Su Küçük; Mustafa Özdemir; Sinem Örnek; Pelin Kuteyla Can; Eda Haşal; Burhan Engin; Nilgün Atakan; Erkan Alpsoy
Journal:  An Bras Dermatol       Date:  2022-07-16       Impact factor: 2.113
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.